Pharmafile Logo
Pharmafocus logo
Advanced Search

breast cancer

Showing 15 posts of 177 posts found.

NICE greenlights Novartis Kisqali combo in HR+/HER2- advanced breast cancer

July 17, 2019
Manufacturing and Production, Medical Communications, Research and Development Cancer, Kisqali, NICE, Novartis, UK, breast cancer, pharma

Novartis’ Kisqali (ribociclib) has secured recommendation from NICE in combination with fulvestrant, meaning the cyclin-dependent kinase 4 and 6 (CDK4/6) …

News

Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation

July 11, 2019
Sales and Marketing Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma

Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after …

News

Roche’s Tecentriq scores CHMP recommendation in PD-L1+ metastatic triple-negative breast cancer

July 2, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Roche, breast cancer, pharma, tecentriq

Roche’s immunotherapy Tecentriq (atezolizumab) has been recommended by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in combination …

News

Pfizer’s Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA1/2 mutations

June 24, 2019
Sales and Marketing Pfizer, breast cancer, oncology, pharma

Pfizer’s oral poly (ADP-ribose) polymerase (PARP) inhibitor Talzenna (talazoparib) has secured approval in Europe from the European Commission, the drugmaker …

News

Novartis’ Kisqali combo boosts survival in HR+/HER2- advanced breast cancer

June 3, 2019
Research and Development, Sales and Marketing Cancer, Kisqali, Novartis, breast cancer, pharma

Novartis took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to reveal new Phase 3 …

News
novartis_side_building

FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer

May 28, 2019
Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma

Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …

News
lilly_entrance_web

Japan’s health ministry warns of serious side effects of Lilly’s Verzenio

May 23, 2019
Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma

Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …

News
merck-keytruda

Keytruda fails to improve overall survival in advanced triple-negative breast cancer

May 21, 2019
Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma, triple-negative breast cancer

MSD has made it known that its cancer immunotherapy Keytruda (pembrolizumab) failed to meet its primary endpoint in a Phase …

News
lynparza

Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer

April 10, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma

Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …

News

FDA approves Pfizer’s Ibrance for advanced male breast cancer

April 5, 2019
Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma

The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …

News
lilly_building_with_american_flag_web

NICE recommends Eli Lilly’s Verzenio in combination with Fulvestrant for breast cancer

April 2, 2019
Manufacturing and Production CDF, Cancer, NICE, breast cancer, britain, oncology

Britain’s cost effectiveness body, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly’s Verzenio (abemaciclib) in …

News
roche__tree

Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer

April 1, 2019
Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq

Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …

News
cancer-cells-541954_960_720

Breast cancer mortality rates fall faster in Britain than elsewhere in Europe

March 19, 2019
Manufacturing and Production, Research and Development Cancer, EU, Europe, France, Italy, Poland, UK, breast cancer, german, oncology

Death rates from breast cancer are falling faster in Britain than in any of the other six most populous countries …

News

FDA approves first diagnostic tool to target triple-negative breast cancer patients

March 11, 2019
Sales and Marketing Cancer, Roche, Ventana, breast cancer, pharma

Roche’s Ventana PD-L1 Assay has become the first FDA-approved companion diagnostic for the identification of patients with triple-negative breast cancer …

News

Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer

January 17, 2019
Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma

Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025